Interferon beta assessment in non-Chinese and Chinese subjects: pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependent.

@article{Rogge2014InterferonBA,
  title={Interferon beta assessment in non-Chinese and Chinese subjects: pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependent.},
  author={Mark C. Rogge and Yun Liu and Gerald R. Galluppi},
  journal={Journal of clinical pharmacology},
  year={2014},
  volume={54 10},
  pages={
          1153-61
        }
}
Interferon beta-1a (IFNβ-1a) is a first-line therapy for relapsing multiple sclerosis when administered as 30 mcg intramuscularly (IM) once weekly. This endogenous cytokine displays pharmacokinetic (PK) attributes consistent with a glycoprotein of 20-kDa molecular weight that is administered IM. In this study, 24 healthy Chinese subjects (11 male, 13 female) each received 4 once-weekly 60-mcg IM doses of IFNβ-1a. Serial blood samples were drawn for PK and pharmacodynamic (PD) assessments… CONTINUE READING